Home urine test kit can accurately spot prostate cancer risk

Cancer test at home on ‘first wee of the day’			
   by Mark Waghorn 

Cancer test at home on ‘first wee of the day’ by Mark Waghorn Published

"Immunotherapy has had tremendous benefits for some cancer patients, and it's fantastic news that even in prostate cancer, where we don't see much immune activity, a proportion of men are responding well to treatment", says Professor Paul Workman, chief executive of The Institute of Cancer Research.

'It implies that men would not need to experience a computerized rectal assessment, so it would be considerably less distressing and should bring about much more patients being tried.

"For the reason that prostate is repeatedly secreting, the selection of urine from males's first urination of the day implies that the biomarker ranges from the prostate are a lot upper and extra constant, so it is a nice growth".

Researchers say the test will be more sensitive than current methods and will be in the form of a collection kit that will enable people to do a urine test in the comfort of their own home.

The Prostate Urine Risk test, developed by British scientists, works by looking at genetic information stored within urine and uses the "first wee of the day" which produces chemicals offering a more accurate analysis.

The scientists' most recent study found the PUR (prostate urine risk) test could be performed on samples collected at home - removing the need for men to visit a clinic to provide a sample or undergo an uncomfortable rectal exam. "And comments from the contributors confirmed that the at-home take a look at was once preferable", printed Clark.

As part of a small study, the researchers gave 14 men at-home collection kits.

Dr Clark stated: 'The PUR test precisely predicts forceful prostate malignancy, and predicts whether patients will require treatment as long as five years sooner than standard clinical techniques.

Dr Clark said: 'The PUR test accurately predicts aggressive prostate cancer, and predicts whether patients will require treatment up to five years earlier than standard clinical methods.

"It usually develops slowly and the majority of cancers will not require treatment in a man's lifetime".

Robert Mills, Consultant Surgeon in Urology at the Norfolk and Norwich University Hospital, said: "This is a very exciting development as this test gives us the possibility of differentiating those who do from those who do not have prostate cancer so avoiding putting a lot of men through unnecessary investigations". A person who is tested negative would need to step into the hospital every two to three years, only facilitating stress-free conditions for the patients and reducing hospital workload.

"When we do diagnose prostate cancer, the urine test has the potential to differentiate those who need to have treatment from those who do not need treatment, which would be invaluable".

'These patients go on to an active surveillance programme following the diagnosis which may involve repeat biopsies and MRI scans which is quite intrusive.

But first, a test to pick out who will respond best is needed, so that doctors know which patients to give it to.

'However, these urine-based biomarkers, although promising and an area of active research, are not yet recommended for prostate cancer screening or during management of prostate cancer by active surveillance. "Should any of these biomarkers become a standard screening or surveillance tool in future, this new "at-home" method will be useful".

There is no national prostate screening program with respect to years the tests have been excessively off base. These findings could also help pioneer the development of home collection tests for bladder or kidney cancer.

The university receives more than 800 referrals a year to investigate the true samples and treat potential prostate cancer.

■ THE number of cancer sufferers in the United Kingdom has risen by almost a fifth in five years to nearly 3million.

Latest News